May 21, 2026
Two different products with the same label
Growth-stage biopharma CEOs often receive the same pitch from two very different firms: “strategic advisory.” One is biopharma consulting led by operators who have run P&L, closed deals, and sat in board rooms. The other is management consulting - a structured firm model with teams, frameworks, and deliverables optimized for breadth and repeatability.
Both can be useful. The mistake is hiring the wrong model for the decision in front of you.
Management consulting: what you are actually buying
Generalist firms bring analytical horsepower, benchmarking, and process. Typical strengths:
- Large teams that can run parallel workstreams on diligence or market landscaping
- Familiar templates for board decks, strategic plans, and operating model reviews
- Brand credibility with investors who recognize the firm name
Trade-offs for growth-stage life sciences:
- Junior staffing on much of the work, with partners appearing at milestones
- Recommendations that reflect industry patterns more than your specific asset, modality, or payer reality
- Timelines driven by the firm's cadence, not your deal or launch clock
If you need a polished board narrative in three weeks and already know the strategic answer, that model can work.
Operator-led biopharma consulting: what changes
Life sciences advisory from operators is a different contract. You are buying judgment from people who have executed under the same constraints you face now - capital raises, M&A integration, launch sequencing, manufacturing scale-up, and board crises.
Katogen's model (and the model CEOs should demand from any specialist advisor):
- The person in the room has done the job, not only advised on it
- Deliverables are built for execution - board memos, deal structures, integration plans, access sequencing - not shelf-ware slides
- Scope is selective; firms that take every engagement are often selling hours, not outcomes
When each model fits
| Situation | Management consulting | Operator-led consulting |
|---|---|---|
| Board wants a market-size and competitor landscape | Often a fit | Optional supplement |
| Preparing for a live M&A process or capital raise | Risky as primary advisor | Strong fit |
| Post-close integration with revenue at risk | Risky as primary owner | Strong fit |
| Launch with payer and pricing decisions in the same quarter | Risky as primary owner | Strong fit |
| CEO needs interim leadership | Not the right tool | Fractional / interim fit |
Questions to ask any advisor before you sign
- Who will do the work week to week - partners only, or a junior team?
- How many transactions, launches, or turnarounds has the lead advisor personally owned?
- Can they show an example deliverable that went to a board or deal team, not only a client workshop?
- What will they recommend you stop doing - not only what to add?
More answers in our biopharma consulting FAQ.
Practical next step
If you are deciding between models for an upcoming decision, start with the biopharma consulting services overview - six practice areas, how engagements run, and when we take work. For a direct conversation, contact Katogen.
